Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High Dose s.c. Semaglutide on Gastric Emptying in Obesity
NCT07845578Phase 1Not yet recruiting
- Sponsor
- Novo Nordisk
- Start
- Sep 2026
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity comparing Semaglutide with Placebo (2 arms). Primary endpoint: Area under the paracetamol plasma concentration-time curve at Day 177. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07845578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07845578.